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Nischarin regulates Rac1-dependent cell motility by
interaction with and inhibition of the p21-activated ki-
nase (PAK1). In addition to regulating the activation of
PAK1, Rac1 controls multiple downstream pathways to
regulate cell growth and differentiation, as well as cell
motility. Signaling by a constitutively activated Rac1
mutant deficient in PAK binding (Rac1Q61L-40C) was
examined to determine whether Nischarin impinges on
these other Rac1 effector pathways. Nischarin formed
immunoprecipitatable complexes with Rac1Q61L and
Rac1Q61L-40C when the proteins were co-expressed.
In NIH3T3 cells, Rac1Q61L and Rac1Q61L-40C stimu-
lation of a minimal NF-B response element or the
cyclin D1 promoter, a downstream target of NF-B,
was inhibited by co-expression of Nischarin. Addition-
ally, suppression of endogenous Nischarin protein
with small interfering RNA in PC12 cells enhanced
Rac1Q61L and Rac1Q61L-40C activation of NF-B. In
further support of Nischarin suppressing PAK inde-
pendent Rac signaling, foci formation in monolayers of
NIH3T3 cells by Rac1Q61L-40C in cooperation with
c-Raf/CAAX was inhibited by the presence of Nischa-
rin. Nischarin alters the cellular localization of
Rac1Q61L and Rac1Q61L-40C to vesicles and this pos-
itively correlates with the repression of the Rac1 sig-
nal. Thus, Nischarin, in addition to regulating the PAK
strand of Rac1 signaling, can also regulate other links
in the web of Rac1 signaling pathways.
The Rho GTPases are a family of 20 proteins that act as
molecular switches that assist in the transduction of signals
through the interior of the cells. Activation of a variety of cell
surface receptors shifts the Rho GTPases from the inactive
GDP bound state to the active GTP bound state through the
activity of numerous guanine nucleotide exchange factors. The
active GTPase can then interact with a myriad of effectors and
modulate their function. GTPase activating proteins suppress
signaling by the Rho GTPases by stimulating the hydrolysis of
GTP to GDP (1, 2).
Rac1 is an important and well studied member of the Rho
GTPase family of proteins. Rac1 signaling regulates numerous
and disparate cellular functions including motility, cell cycle tra-
verse, cytoskeletal remodeling, endocytosis, and cellular trans-
formation (2–7). To mediate these effects on cellular phenotype,
Rac1 interacts with a variety of effector proteins. For example,
Rac1 regulation of cell motility is mediated, in part, by interac-
tion with the family of p21-activated kinases (PAK).1 Activated
PAK stimulates the formation of cortical actin networks, which
are important for Rac-induced lamellipodia, by suppressing the
actin-depolymerizing activity of cofilin via the activation of LIM
kinase. PAK also readies the cell for movement by suppressing
stress fiber formation and increasing focal adhesion turnover, in
part, by disrupting the actin myosin network through inactiva-
tion of myosin light chain kinase (8). Independently from PAK,
Rac1 interacts with the dormant, multiprotein WAVE complex
through PIR121 and Nap125, to stimulate the dissociation of
WAVE and allowing it to activate the actin polymerizing Arp2/3
complex. Rac has also been found to complex with WAVE
through IRSp53 to modulate WAVE function (9, 10). Similarly,
Rac1 can regulate proliferative signals through various means
such as activation of PAK and its subsequent phosphorylation of
Raf/mitogen-activated protein kinase components or via other
mechanisms, such as stimulation of NF-B through the NF-B
inducing kinase (11–16).
Nischarin was cloned from a mouse embryonic cDNA library
using the cytoplasmic domain of the integrin 5 subunit as
“bait” (17). Nischarin interacts directly with 5 through mem-
brane proximal residues of the 5 cytoplasmic domain (18).
Elevated levels of intracellular Nischarin impede 5-dependent
cell motility in fibroblast and epithelial cells (17). Overexpres-
sion of Nischarin inhibits Rac1-stimulated cell motility and
this directly correlates with its ability to inhibit signaling via
the Rac1 effector PAK1 (18, 19). Nischarin preferentially binds
activated PAK1 and forms a complex with PAK1 via its N
terminus and the kinase domain of PAK. The association of
Nischarin with PAK1 inhibits PAK1 activation and, thus,
PAK1-stimulated migration (20).
As described above, in addition to PAK, Rac1 has multiple
downstream effectors and can act independently of PAK to
regulate processes such as cell proliferation and transforma-
tion (2, 3, 6, 16, 21). Using a PAK binding-deficient mutant of
Rac, Rac1Q61L-40C, we have found that Nischarin can interact
with activated Rac independently of its interaction with PAK.
This interaction is functionally important because Nischarin
inhibits PAK-independent Rac1 signal transduction and cell
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transformation. Thus, in addition to regulating the PAK1 arm
of Rac signal transduction, Nischarin may regulate Rac1 sig-
naling via other Rac effector pathways.
MATERIALS AND METHODS
Cell Culture—COS-7 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 4,500 mg/liter D-glucose and sodium pyruvate
supplemented with L-glutamine and 10% fetal bovine serum (Sigma).
NIH3T3 cells were cultured in DMEM supplemented with L-glutamine
and 10% calf serum (Colorado Serum Company, Denver, CO). PC12 cells
were cultured in DMEM with 10% horse serum (GIBCO®, Invitrogen Cell
Culture, Carlsbad, CA) and 5% fetal bovine serum.
Vectors—The cDNA for full-length mouse nischarin, the N terminus
(aa 1–802), and the C terminus (aa 970–1354) were inserted at the
EcoRV/NotI sites in the multiple cloning site of pcDNA3.1 B Myc/His
(pcDNA) (Invitrogen). Full-length human PAK1 cDNA (provided by
J. Chernoff) and -galactosidase were expressed from pcDNA3.1 B
Myc/His. Myc-GFP was expressed from the pCMV/myc/cyto/GFP vector
from Invitrogen. HA-tagged Rac1Q61L, HA-Rac1Q61L-40C, and c-Raf/
CAAX (provided by C. Der) were expressed from the pCGN vector (21).
The AU5-Rac1 wild type expression vector was provided by K. Burridge.
The NF-B reporter plasmid (3NF-B-LUC) contains three repeats of
the NF-B site from the human immunodeficiency virus-long terminal
repeat ligated into the pGL2-Promoter plasmid (Promega, Madison,
WI). The 963/134 cyclin D1-luciferase reporter construct (963-
CD1LUC) was provided by R. Pestell (21).
Immunoprecipitation—For Nischarin/Rac1 binding, COS-7 cells
were transfected with 1 g of Myc-Nischarin plasmid and 0.5 g of
HA-Rac1Q61L or HA-Rac1Q61L-40C plasmids using FuGENE 6
(Roche). After 48 h, the cells were lysed in Rac lysis buffer (50 mM
Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol, 1%
Nonidet P-40) with protease and phosphatase inhibitors. The lysates
were pre-cleared with Protein G-Sepharose® (Amersham Biosciences)
and then incubated with a 1:100 dilution of anti-Myc antibody (9E10,
Covance Research Products, Berkeley, CA) or anti-HA antibody (HA.11,
Covance) at 4 °C for 2 h. The immune complexes were precipitated with
Protein G-Sepharose®, and the precipitates were resolved on a 4–20%
gradient gel. The immunoprecipitated proteins were detected with the
antibodies used for the various epitope tags with ECLTM (Amersham
Biosciences) using standard techniques. For the immunoprecipitation
of endogenous Rac1, exponentially growing PC12 cells were lysed in the
Rac lysis buffer  0.1% Triton X-100. A 1:100 dilution of an anti-Rac1
monoclonal antibody was used to immunoprecipitate Rac1 as described
above (anti-Rac1, clone 23A8, Upstate Cell Signaling Solutions, Lake
Placid, NY). Normal mouse IgG from Santa Cruz Biotechnology was
used at an equivalent concentration in parallel as a control. The immu-
noprecipitated Rac1 was detected with the same antibody, and the
bound Nischarin was detected with a rabbit polyclonal antibody gener-
ated against a Nischarin peptide (aa 219–236).
Stimulated Rac/Nischarin Interaction—COS-7 cells were trans-
fected with 2 g of Myc-Nischarin plasmid and 1 g of AU5-Rac1 using
FuGENE 6. Twenty-four hours after the beginning of the transfection,
the plates were washed twice with phosphate-buffered saline (PBS) and
placed in serum-free DMEM for 18 h. The cells were treated with 25
ng/ml recombinant human epidermal growth factor (EGF) for 10 min
(Upstate Cell Signaling Solutions). The cells were lysed in Rac lysis
buffer plus 0.1% Triton X-100. Myc-Nischarin was immunoprecipitated
with a 1:100 dilution of 9E10 monoclonal antibody. The blots were
probed with a biotinylated, monoclonal anti-AU5 antibody (Covance)
and detected with streptavidin-horseradish peroxidase conjugate and
ECLTM (Amersham Biosciences).
Reporter Gene Assays—NIH3T3 cells were plated in 6-well plates at
1  105 cells per well and grown overnight. The cells were transiently
transfected with 3 g of plasmid for Myc-Nischarin, Myc-N terminus,
Myc-C terminus, or Myc--galactosidase and 1 g of HA-Rac1Q61L,
HA-Rac1Q61L-40C, or pCGN plasmid, and 1 g of 3NF-B-LUC or
963-CD1LUC plasmid with SuperFectTM (Qiagen, Valencia, CA).
Twenty-four hours after transfection the cells were washed with PBS
and incubated overnight in DMEM  0.5% calf serum. After starvation,
the cells were washed with PBS and lysed in 150 l of 1 Reporter
Lysis Buffer (Promega). The luciferase activity was measured using the
Luciferase Assay System from Promega on a Monolight 2010 luminom-
eter (Analytical Luminescence Laboratory, San Diego CA).
For PC12 cells, 12-well plates were coated with 0.5 ml of 20 g/ml
collagen in 30% ethanol and dried overnight. The coated plates were
seeded with 4  105 cells and grown overnight. The cells were trans-
fected with LipofectamineTM 2000 (Invitrogen) with 900 ng of plasmid
for Myc-Nischarin or Myc--galactosidase and 300 ng of HA-Rac1Q61L,
HA-Rac1Q61L-40C, or pCGN plasmids and 300 ng of 3NF-B-LUC.
Twenty-four hours after transfection the cells were washed with PBS,
starved in serum-free DMEM for 12–15 h, harvested, and assayed for
luciferase activity.
For suppression of endogenous Nischarin protein levels by siRNA, a
previously described 21-base pair siRNA oligonucleotide for rat Nischa-
rin, rCrCUrCrGUrGrCrArCrCUUrGrArCrCUrGTT (20), or a nonspe-
cific control duplex siRNA (#D-001206-07-20) were synthesized by
Dharmacon, Lafayette, CO. The siRNA oligomers at a concentration of
150 nM were co-transfected with 500 ng of HA-Rac1Q61L, HA-
Rac1Q61L-40C, or pCGN plasmid and 500 ng of 3NF-B-LUC into
PC12 cells with LipofectamineTM 2000 as described above. Forty-eight
hours after transfection the cells were washed with PBS, starved in
serum-free DMEM for 12–15 h, harvested, and assayed for luciferase
activity. Nischarin levels were determined with a monoclonal anti-
Nischarin antibody (BD Biosciences). -Tubulin was detected with a
monoclonal anti--tubulin antibody (Sigma). All of the luciferase assays
were performed in triplicate, and the luciferase activity was normalized
to protein levels.
Foci Forming Assays—NIH3T3 cells were plated in 60-mm dishes at
4  105 cells per plate. The cells were transfected with 1 g of
Rac1Q61L-40C, 100 ng of c-Raf-CAAX, both, or the pCGN vector control
and 2 g of Myc-Nischarin or pcDNA using SuperFectTM. The cells were
kept at confluence for 21–24 days with media changes every 3–4 days.
The colonies were visualized and counted after staining with 0.1%
crystal violet. The experiments were performed with triplicate or quad-
ruplicate plates for each treatment.
Confocal Microscopy—NIH3T3 cells were plated in 6-well plates at
2  105 cells per well and grown overnight. The cells were transiently
transfected with 3 g of Myc-Nischarin, Myc-N terminus, Myc-C ter-
minus, or pcDNA vectors and 1 g of HA-Rac1Q61L, HA-Rac1Q61L-
40C, or pCGN with LipofectamineTM 2000 (Invitrogen). After 24 h of
transfection, the cells were trypsinized, and half of the cells were
replated on fibronectin-coated coverslips (10 g/ml) in DMEM  10%
calf serum, and grown overnight. The cells were washed with PBS, fixed
in 3% paraformaldehyde, permeabilized in 0.5% Triton X-100, and
blocked in 2% bovine serum albumin for 1 h at room temperature. The
coverslips were stained with FITC-conjugated anti-Myc (9E10) and
Alexa 594-conjugated anti-HA (HA.11) antibodies (Covance) for 1 h at
room temperature. The coverslips were washed with PBS and rinsed
with H2O. The stained cells were observed on an Olympus Confocal
FV300 fluorescent microscope with a 60 oil immersion objective; im-
ages were acquired by using Olympus Fluoview software.
RESULTS
Nischarin Interacts with Rac1 Independently of PAK—Nis-
charin directly interacts with activated PAK1 and suppresses
PAK1 kinase activity. Additionally, co-expression of activated
Rac1 with PAK1 and Nischarin stimulates association of PAK1
with Nischarin without preventing association of Rac1 with
PAK1. All three proteins can be found in Nischarin immuno-
precipitates from cells overexpressing Nischarin, PAK1, and
activated Rac1 (20).
The presence of Rac1 in the Nischarin-PAK1 intracellular com-
plex may solely depend on the association of Rac1 with PAK1.
Alternatively, Rac1 could associate with Nischarin through
PAK1-independent interactions. Overexpression of HA-tagged,
constitutively activated Rac1 (HA-Rac1Q61L) with Myc-tagged
Nischarin (Myc-Nischarin) in the absence of exogenous PAK1 in
COS-7 cells allowed co-precipitation of Myc-Nischarin with the
immunoprecipitated HA-Rac1Q61L (Fig. 1A). Conversely, immu-
noprecipitation of Myc-Nischarin also co-precipitates HA-
Rac1Q61L (Fig. 1B). Nischarin does not exhibit detectable inter-
action with the unrelated protein, HA-ERK1, under these
experimental conditions nor does HA-Rac1Q61L interact with
Myc-GFP. This indicates that the Nischarin/Rac1 interaction is
specific. The retention of the Rac1/Nischarin interaction in the
absence of exogenously expressed PAK1 suggests that the bind-
ing of Rac1 to Nischarin may have a PAK-independent compo-
nent because the levels of endogenous PAK are unlikely to be
sufficient to mediate this interaction.
To directly test if the interaction of Nischarin with Rac1
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required PAK1, a PAK binding-deficient mutant of Rac1, HA-
Rac1Q61L-40C, was used. Several laboratories have used this
Rac1 effector domain mutant to investigate PAK-independent
functions of Rac1 (16, 21). Myc-Nischarin and Myc-PAK1 were
co-expressed in COS-7 cells with HA-Rac1Q61L or HA-
Rac1Q61L-40C. Immunoprecipitation of Nischarin or PAK1 by
their Myc epitopes consistently co-precipitated HA-Rac1Q61L.
In agreement with previous studies (16, 21), HA-Rac1Q61L-
40C did not co-precipitate with immunoprecipitated PAK1.
However, HA-Rac1Q61L-40C was repeatedly co-immunopre-
cipitated with Nischarin (Fig. 1C). Thus, the complex formation
between Nischarin and active Rac1 does not require the inter-
action of Rac1 with PAK. Previously described Rac1 effector
domain mutants (E31V, F37L, and N43D) were also examined
in the co-immunoprecipitation assay and they did not abrogate
the Rac1/Nischarin interaction (data not shown) (16, 21).
To determine whether Nischarin and Rac1 can interact at
the normal, endogenous levels of the proteins, PC12 cells were
used because Nischarin is expressed well in PC12 cells (17, 20).
Lysates were made from exponentially growing cells, and Rac1
was immunoprecipitated with a Rac1-specific monoclonal anti-
body. The endogenous Nischarin was co-immunoprecipitated in
four separate experiments (Fig. 1D). Thus, the interaction be-
tween Rac1 and Nischarin occurs at physiological levels
of expression.
Nischarin interacts with 5 integrin and PAK1 through
overlapping domains in the N terminus (aa 1–802) of the pro-
tein (20). To determine which region of Nischarin Rac1 inter-
acts, Myc-tagged forms of the N and C terminus of Nischarin
(aa 970–1354) were co-expressed with HA-Rac1Q61L in COS-7
cells. The N terminus of Nischarin consistently co-immunopre-
cipitated with HA-Rac1Q61L when expressed in COS-7 cells.
The C terminus also co-immunoprecipitated with HA-
Rac1Q61L, but with reduced efficiency (Fig. 2A). Immunopre-
cipitation of the Nischarin fragments via the Myc epitope pro-
duced a similar binding pattern (data not shown).
The HA-Rac1Q61L-40C mutant exhibited a similar co-im-
munoprecipitation pattern with Nischarin and its fragments as
HA-Rac1Q61L (Fig. 2B). Thus, the formation of Nischarin in-
tracellular complexes with activated Rac1 by either domain of
Nischarin does not require the interaction of Rac1 with PAK
and the 40C substitution does not alter the interaction of Rac1
with either domain. Additionally, the interaction of Rac1 with
the C terminus of Nischarin supports the PAK-independent
nature of this interaction because PAK1 exhibited no interac-
tion with the C terminus of Nischarin (20).
Growth Factor-stimulated Interaction of Rac and Nischa-
rin—Rac switches to its activated state in response to signals
from various cell surface receptors (2, 3). To test if a natural cell
stimulus could stimulate the Rac1/Nischarin interaction, COS-7
cells co-expressing wild type AU5-Rac1 and Nischarin were
treated with EGF. The cells were harvested after 10 min of
treatment with EGF. Myc-Nischarin was immunoprecipitated
and the precipitates were examined for the presence of AU5-
Rac1. Rac1 was detected in the Myc-Nischarin immunoprecipi-
tate after EGF stimulation (Fig. 3). This mimicked the stimu-
lated binding of PAK1 to Rac1 in parallel immunoprecipitations.
This EGF-stimulated interaction between Rac1 and Nischarin
points to an important physiological role for this interaction.
Nischarin Regulation of PAK-independent Rac Signaling—
The observation of a PAK-independent interaction between
Nischarin and Rac1 suggested that Nischarin may be able to
regulate Rac1 functions that are not dependent on PAK for
their execution. NIH3T3 cells have been used in conjunction
FIG. 1. Nischarin co-precipitates
with activated Rac1. A, COS-7 cells
were co-transfected with Myc-tagged Nis-
charin, PAK1, or GFP and HA-Rac1Q61L
or HA-ERK1 expression vectors. Forty-
eight hours after transfection cells were
lysed in Rac lysis buffer and immunopre-
cipitated (IP) with a 1:50 dilution of the
monoclonal HA antibody. The blot was
probed with anti-Myc or anti-HA antibod-
ies as indicated. B, activated Rac1 co-pre-
cipitates with Nischarin. COS-7 cells
were co-transfected with Myc-Nischarin,
Myc-PAK1, or Myc-GFP and HA-
Rac1Q61L or HA-ERK1 vectors. Forty-
eight hours after transfection cells were
lysed in Rac lysis buffer and immunopre-
cipitated with a 1:100 dilution of the anti-
Myc antibody. The blot was probed with
anti-HA or anti-Myc antibodies as indi-
cated. C, Nischarin co-precipitates with
PAK binding-deficient HA-Rac1Q61L-
40C. Myc-Nischarin or Myc-PAK1 and
HA-Rac1Q61L or HA-Rac1Q61L-40C vec-
tors were co-transfected into COS-7 cells.
The cells were treated and harvested as in
A, and Nischarin or PAK1 were immuno-
precipitated in parallel with a 1:100 dilu-
tion of the anti-Myc antibody. The blots
were probed for the Myc and HA epitopes
as indicated. D, endogenous interaction of
Nischarin and Rac1. Exponentially grow-
ing PC12 cells were harvested in Rac lysis
buffer  0.1% Triton X-100. Rac1 was
immunoprecipitated with a monoclonal
Rac1 antibody from the cleared lysates.
An equivalent amount of lysate was incu-
bated with an equal concentration of nor-
mal mouse IgG in parallel. Nischarin was
detected by immunoblotting with a poly-
clonal anti-Nischarin antibody.
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with the Rac1Q61L-40C effector domain mutant to identify
PAK-independent pathways downstream of Rac1 (16, 21, 22).
One Rac1 pathway that appears to be independent of PAK in
NIH3T3 cells is the NF-B pathway (12, 23, 24). We examined
the effect of Nischarin on Rac1 stimulation of NF-B using a
3NF-B response element linked to a luciferase reporter con-
struct, 3NF-B-LUC. Expression of activated Rac1Q61L or
Rac1Q61L-40C in NIH3T3 cells stimulated the NF-B re-
sponse element 5- and 6-fold, respectively (Fig. 4A). An acti-
vated mutant of PAK1, PAK1-T423E, which mimics the kinase
domain activation loop phosphorylation, was unable to stimu-
late 3NF-B-LUC. This underscores the PAK independence
of the NF-B signaling in NIH3T3 cells. Co-expression of Nis-
charin with Rac1Q61L or Rac1Q61L-40C suppressed the Rac1-
stimulated NF-B response by 59 and 73%, respectively. Ex-
pression of the N terminus also significantly suppressed
Rac1Q61L activation of NF-B by 72% and Rac1Q61L-40C
stimulation by 80%. However, expression of the C terminus did
not suppress the activation of NF-B by either form of activated
Rac (Fig. 4A). Thus, the N terminus of Nischarin inhibits
Rac1-mediated stimulation of the NF-B pathway independ-
ently of PAK function.
Activated Rac1 stimulates cyclin D1 gene expression. This
stimulation can occur independently of PAK activation and is
mediated in part by NF-B activation (21, 23, 25). Co-transfec-
tion of 963-CD1LUC with Rac1Q61L or Rac1Q61L-40C, re-
spectively, stimulated the cyclin D1 promoter by 10- and 7-fold
(Fig. 4B). Expression of PAK1-T423E had little effect on the
level of cyclin D1 promoter activity. Co-expression of Nischarin
with Rac1Q61L suppressed cyclin D1 promoter activation by
46%. Rac1Q61L-40C-stimulated cyclin D1 promoter activation
was inhibited 58% by co-transfected Nischarin. The N terminus
of Nischarin suppressed Rac1Q61L stimulation of the cyclin D1
promoter by 73% and it inhibited the Rac1Q61L-40C stimula-
tion by 78%. Co-expression of the C terminus of Nischarin with
either activated Rac1 did not suppress the activation of the
cyclin D1 promoter (Fig. 4B). Thus, the ability of Nischarin to
inhibit the Rac1-stimulated cyclin D1 maps to the N terminus
and does not require Rac1 to PAK signaling.
To determine whether the physiological role of Nischarin in
Rac signal transduction is to act as a suppressor of Rac1 sig-
naling, the effect of siRNA suppression of endogenous Nischa-
rin on NF-B activation by Rac1 was examined in PC12 cells.
Similar to the observations in NIH3T3 cells, the overexpression
of Nischarin in PC12 cells with Rac1Q61L or Rac1Q61L-40C
suppressed Rac1 stimulation of the NF-B pathway by 50 and
FIG. 2. Separate regions of Nischarin interact with Rac1 inde-
pendently from PAK. A, Rac1 co-precipitates with both the N and C
terminus of Nischarin. COS-7 cells were co-transfected with expression
vectors for Myc-Nischarin, Myc-N terminus, Nis-C terminus, or Myc--
galactosidase and HA-Rac1Q61L or ERK1. Forty-eight hours after
transfection cells were lysed in Rac lysis buffer and immunoprecipi-
tated (IP) with 1:100 dilution of the monoclonal anti-HA antibody. The
blot was probed with anti-HA or anti-Myc antibodies as indicated. B,
Rac1 interacts with the N and C terminus of Nischarin independently
from PAK. Myc-Nischarin, Myc-N terminus, or Myc-C terminus were
expressed in COS-7 cells with HA-Rac1Q61L, HA-Rac1Q61L-40C, or
HA-ERK1. The cells were solubilized in Rac lysis buffer and immuno-
precipitated with the anti-Myc antibody. The immunoprecipitates were
subjected to Western analysis and blotted for the respective epitope
tags.
FIG. 3. Stimulation of Nischarin/Rac1 interaction by EGF
treatment. Myc-Nischarin or Myc-PAK1 were expressed with wild-
type AU5-Rac1 in COS-7 cells. A day after transfection the cells were
starved for 24 h in serum-free DMEM. The cells were stimulated with
EGF at 25 ng/ml for 10 min. The cells were lysed in the Rac lysis buffer
with 0.1% Triton X-100. The lysates were immunoprecipitated with
anti-Myc monoclonal antibody. The immunoprecipitates were subjected
to Western analysis and probed for the AU5 and Myc epitopes.
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37%, respectively (Fig. 4C). Co-transfection of siRNA for Nis-
charin with either Rac1Q61L or Rac1Q61L-40C in PC12 cells
elevated the level of Rac1 stimulation of the NF-B pathway by
2.2-fold for Rac1Q61L and 1.6-fold for Rac1Q61L-40C com-
pared with the level of NF-B activation in cells transfected
with control siRNA (Fig. 4D). This elevation of the Rac-stimu-
FIG. 4. Nischarin inhibition of Rac1-stimulated NF-B response element and cyclin D1 promoter activation. A, inhibition of
Rac1-stimulated NF-B activity by Nischarin. Nischarin, the N terminus, C terminus, or -galactosidase were co-transfected with Rac1Q61L,
Rac1Q61–40C, pCGN, or Pak1-T423E (Nis:Rac  3:1) and the 3NF-B-LUC reporter vector into NIH3T3 cells. The cells were allowed to recover
overnight in complete media and then were starved for 20 h in DMEM  0.5% calf serum. The luciferase activity was measured and normalized
to protein levels. The data are from three to four experiments performed in triplicate. The normalized luciferase activities in the cells transfected
with pCGN and the -galactosidase plasmid were used as the control and set equal to 1. B, inhibition of Rac1-stimulated cyclin D1 promoter
activity by Nischarin. Nischarin, the N terminus, C terminus, or -galactosidase were expressed with Rac1Q61L, Rac1Q61–40C, pCGN, or
Pak1-T423E (Nis:Rac  3:1) and a 963-CD1LUC reporter in NIH3T3 cells. The cells were allowed to recover overnight. The cells were starved
for 20 h in 0.5% calf serum. The luciferase activity was determined and normalized as in A. The data are from three to five experiments performed
in triplicate. C, inhibition of Rac1-stimulated NF-B activity by Nischarin in PC12 cells. Nischarin or -galactosidase were co-transfected with
Rac1Q61L, Rac1Q61–40C, or pCGN (Nis:Rac  3:1) and the 3NF-B-LUC reporter vector into PC12 cells. The cells were allowed to recover
overnight and then were starved for 12–15 h in serum-free DMEM. The luciferase activity was determined and normalized as in A. The data are
from four experiments performed in triplicate. In A–C, p  0.05, for the difference in -fold activation of Rac1Q61L or Rac1Q61–40C in the presence
of -galactosidase compared with the -fold activation in the presence of Nischarin or the N terminus; unpaired Student’s t test. D, stimulation of
Rac1-mediated NF-B activation by suppression of endogenous Nischarin levels. PC12 cells were co-transfected with Nischarin or nonspecific
control siRNA and with Rac1Q61L, Rac1Q61–40C, or pCGN (Nis:Rac  3:1) and the 3NF-B-LUC reporter vector. The cells were grown for 48 h
post-transfection and then starved for 12–15 h in serum-free DMEM. The luciferase activity was determined as in A. The normalized luciferase
activity in the presence of siRNA alone was used as the control and set equal to 1. The data are from six to seven experiments performed in
triplicate (*, p  0.05, for the -fold activation for HA-Rac1Q61L or HA-Rac1Q61L-40C in the presence of control siRNA compared with Nischarin
siRNA; unpaired Student’s t test). The data in A–D are presented as mean  S.E. E, suppression of Nischarin by siRNA transfection into PC12
cells. Lysates from two independent Nischarin siRNA-treated samples and two independent control siRNA-treated samples from the reporter
assays in D were subjected SDS-PAGE and immunoblotted. The blots were probed for the presence of Nischarin and -tubulin as indicated.
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lated NF-B response inversely correlated with the siRNA
suppression of endogenous Nischarin (Fig. 4E). This data un-
derscores the role of Nischarin as a physiological repressor of
Rac1 signaling.
Nischarin Inhibition of Rac1-stimulated Transformation—
Activated Rac can transform NIH3T3 cells in cooperation with
another activated oncogene, such as c-Raf (21). This transfor-
mation of NIH3T3 cells by Rac1 can occur independently of
PAK activation. Furthermore, PAK1 does not cooperate with
activated Raf to transform NIH3T3 cells (21, 22). To determine
whether Nischarin could suppress this PAK independent func-
tion of Rac1, the formation of transformed foci in the absence
and presence of Nischarin was assayed. NIH3T3 cells were
co-transfected with Rac1Q61L and c-Raf-CAAX at a ratio of
10:1 and Nischarin or -galactosidase expression vectors. The
focus forming activity of the various combinations were as-
sayed 22–24 days after transfection. The combination of
Rac1Q61L-40C and c-Raf-CAAX increased the level of focus
formation by 3.6-fold over background. The presence of Nischa-
rin with Rac1Q61L-40C and c-Raf-CAAX suppressed their fo-
cus forming activity by 55% (Fig. 5). Thus, Nischarin can sup-
press Rac1 transformation in NIH3T3 cells independently from
PAK function.
Co-localization of Rac1 and Nischarin in NIH3T3 Cells—The
proper cellular localization of Rac1 is important for efficient
transmission of its signal (26–29). Integrin-directed transloca-
tion of activated Rac to lipid-rich rafts in the plasma membrane
appears to be critical for Rac1 signaling (26, 27, 29). Addition-
ally, Rac1 translocation to the endosomal compartment and the
nucleus may be important in the regulation of Rac1 signaling
(29–31).
NIH3T3 cells were transfected with Myc-Nischarin and HA-
Rac1Q61L or HA-Rac1Q61L-40C. Following a time course sim-
ilar to the NF-B and cyclin D1 regulation experiments, the
localization of Nischarin and Rac1Q61L were examined 2 days
post-transfection. Cells expressing Nischarin alone exhibited
two distinct patterns of staining. In the majority of the cells
Nischarin displayed a diffuse cytoplasmic appearance with mi-
nor nuclear staining. In a subset of cells Nischarin displayed a
vesicular staining pattern in addition to the general diffuse
cytoplasmic staining. The cells expressing Nischarin generally
retained their fibroblast phenotype (Fig. 6A). Expression of
Rac1Q61L in NIH3T3 stimulated the classic Rac phenotype of
well spread cells with numerous membrane ruffles. Rac1Q61L
in NIH3T3 cells was found throughout the cytoplasm, the nu-
cleus, some vesicles, and in membrane ruffles (Fig. 6A). Ex-
pression of both Nischarin and Rac1Q61L led to strong co-
localization of the two proteins. They co-localized to numerous
vesicular structures and in the cytoplasm. The co-localization
did not normally extend to the plasma membrane. The Nischa-
rin staining extended from the perinuclear region and stopped
prior to membrane protrusions, whereas the Rac1Q61L stain-
ing could be found at the plasma membrane. Nischarin did not
localize to the nucleus with Rac1Q61L, which displayed vari-
able levels of nuclear staining (Fig. 6B). A subset of cells did not
exhibit the vesicular structures, but still displayed the strong
cytoplasmic co-localization. Cells expressing both Nischarin
and Rac1Q61L displayed variable phenotypes, but they were
generally intermediate between the Nischarin and Rac1Q61L
alone phenotypes. The expression of Rac1Q61L-40C in NIH3T3
cells induced morphological changes similar to that of
Rac1Q61L with the addition of more filopodial protrusions (Fig.
6A). Nischarin exhibited a similar pattern of co-localization
with Rac1Q61L-40C as that seen with Rac1Q61L. The proteins
were found to co-localize in vesicles and in the cytoplasm with
the co-localization extending from the perinuclear region to just
short of the plasma membrane. As with Rac1Q61L, a portion of
the cells did not exhibit the vesicular structures but still dis-
played the strong cytoplasmic co-localization. The morphologi-
cal changes induced by Rac1Q61L-40C were muted, but not
eliminated, by the co-expression of Nischarin (Fig. 6C).
The localization pattern of the N and C terminus in NIH3T3
cells was examined to determine whether this varied from
Nischarin itself. When expressed alone, the N terminus exhib-
ited a staining pattern similar to that of Nischarin. All of the
cells exhibited strong cytoplasmic and weak nuclear staining
with a subset of the cells exhibiting the vesicular structures
similar to full-length Nischarin (Fig. 6A). The C terminus
showed a widespread, diffuse staining pattern with the nucleus
and cytoplasm containing protein. The C terminus never ex-
hibited the vesicular structures seen with Nischarin or its N
terminus (Fig. 6A).
Co-expression of Rac1Q61L or Rac1Q61L-40C with the N
terminus led to a pattern of co-localization similar to that of
full-length Nischarin. Activated Rac1Q61L-40C and the N ter-
minus displayed cytoplasmic and vesicular co-localization. The
cytoplasmic co-localization did not extend to the plasma mem-
brane; Rac1 was detected at the membrane in ruffles, but the N
terminus staining stopped prior to reaching the membrane.
The N terminus also did not co-localize with nuclear Rac1 (Fig.
6D, data not shown). Thus, Nischarin and its N terminus,
which suppress Rac1 signaling, exhibit the same pattern of
vesicular co-localization with Rac1.
Expression of the C terminus and Rac1Q61L-40C together
produced a broad pattern of staining. Rac1Q61L-40C and the C
terminus were seen in the nucleus and the cytoplasm, more
FIG. 5. Inhibition of Rac1Q61L-40C-
stimulated focus formation by Nis-
charin. NIH3T3 cells were transfected
with 1 g of HA-Rac1Q61L-40C vector,
100 ng of c-Raf-CAAX vector, both, or vec-
tor controls (pCGN) and 2 g of Myc--
galactosidase or Myc-Nischarin vector.
The cells were kept at confluence for
22–24 days with media changes every 3–4
days. The transformed foci were visual-
ized after staining with 0.1% crystal vio-
let. The data are from four experiments
performed with triplicate or quadrupli-
cate plates. The data are presented as
mean  S.E. The level of foci formation
for the vector controls, Myc--galactosid-
ase/pCGN, was set equal to 1 (*, p  0.05,
for Nischarin/HA-Rac1Q61L-40C/c-Raf-
CAAX compared with -galactosidase/
HA-Rac1Q61L-40C/c-Raf-CAAX; unpaired
Student’s t test).
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strongly in the perinuclear region. Additionally, the presence of
the C terminus was detected in membrane ruffles with
Rac1Q61L-40C. Unlike Nischarin or the N terminus, the non-
inhibitory C terminus exhibited no detectable vesicular co-
staining with Rac1Q61L-40C in cells co-expressing these pro-
teins. Rac1Q61L exhibited a similar pattern of staining with
the C terminus when they were expressed together in NIH3T3
cells (Fig. 6E, data not shown).
DISCUSSION
Nischarin appears to be an important modulator of Rac1-
regulated signal transduction pathways. Nischarin suppresses
Rac1-stimulated migration by directly interacting with the ki-
nase domain of PAK1 and inhibiting the kinase activity of PAK1
(20). In this work, we demonstrate that Nischarin also regulates
Rac1 signal transduction pathways that are PAK independent.
Nischarin interacts with Rac1 in its activated state. Both the
N and C terminus of Nischarin exhibit the ability to form a
complex with active Rac1. The intracellular interaction be-
tween Nischarin and Rac1 does not require the interaction of
PAK with Rac1 because the PAK binding-deficient mutant,
Rac1Q61L-40C, also binds to Nischarin through interactions
with both the N and C termini. Activated PAK interacts with
Nischarin via multiple contacts in the N terminus, but PAK
makes no detectable contacts with the C terminus (20). Thus,
the formation of intracellular Rac1-Nischarin complexes, al-
though not absolutely requiring PAK, would likely be facili-
tated by both PAK-dependent and PAK-independent interac-
tions with Nischarin. Furthermore, the interactions between
these three proteins are not mutually exclusive because Nis-
charin, PAK1, and Rac1 can be co-immunoprecipitated from
cells in the presence of activated Rac1, but the interaction of
Nischarin with PAK1 or Rac1 does not require the binding of
the other protein to Nischarin (20).
In NIH3T3 cells Rac1 has the ability to signal to multiple
effector pathways that are not dependent on activation of PAK
(16, 21). The activation of NF-B function and the cyclin D1
promoter positively correlate with cellular transformation by
Rac1 (23, 32). Importantly, the activation of these pathways also
appears to be important in human cancer (33). Rac1 activation of
these pathways in NIH3T3 cells does not require PAK activation
(21, 23, 24). The interaction of Nischarin with Rac1Q61L-40C
suppresses the ability of Rac1 to stimulate the function of NF-B,
the cyclin D1 promoter, and the formation of foci. Thus, the
ability of Nischarin to suppress these pathways does not require
Nischarin repression of PAK function. The enhanced Rac1 to
NF-B signal after repression of endogenous Nischarin levels in
FIG. 6. Co-localization of Rac1 and
Nischarin. A, NIH3T3 cells were trans-
fected with Myc-Nischarin, Myc-N termi-
nus, Myc-C terminus, HA-Rac1Q61L-
40C, or HA-Rac1Q61L expression vectors
or the control vectors as indicated. The
transfected cells were grown overnight on
fibronectin-coated coverslips. The cells
were fixed, and the expressed proteins
were detected with FITC-Myc and Alexa
594-HA monoclonal antibodies and im-
aged with an Olympus confocal fluores-
cence microscope. Arrowheads indicate
vesicular localization of Nischarin and
the N terminus in the Myc-stained cells.
Arrows point to localization of active Rac
to membrane ruffles in HA-stained cells.
B, NIH3T3 cells were transfected with
Myc-Nischarin and HA-Rac1Q61L vec-
tors and stained with FITC-Myc and
Alexa 594-HA antibodies as in A. The co-
localization of the stained images is
shown in the last panel marked MERGE.
C, NIH3T3 cells were transfected with
Myc-Nischarin and HA-Rac1Q61L-40C
vectors, stained with FITC-Myc and
Alexa 594-HA antibodies, and co-localized
as in A. D, NIH3T3 cells were transfected
with Myc-N terminus and HA-Rac1Q61L-
40C vectors, stained with FITC-Myc and
Alexa 594-HA antibodies, and co-localized
as in A. E, NIH3T3 cells were transfected
with Myc-C terminus and HA-Rac1Q61L-
40C and stained with FITC-Myc and Al-
exa 594-HA and co-localized as in A. For
B–E, arrowheads indicate areas of vesic-
ular co-localization of Myc-Nischarin and
HA-Rac1Q61L or HA-Rac1Q61L-40C. In
all panels, the white bar equals 10 m.
Nischarin Regulation of Rac1 Signaling31000
PC12 cells supports the physiological importance of the inhibi-
tory role of Nischarin in Rac signal transduction.
Integrins signal to NF-B through phosphatidylinositol 3-ki-
nase and Rac1 (34). Rac1, as well as Cdc42 and RhoA, can
stimulate the phosphorylation of IB, an inhibitor of NF-B
function, leading to its degradation and NF-B activation (35,
36). The phosphorylation of IB downstream of active Rac1 is
mediated by the activation of the IB kinase  through Rac1
activation of the NF-B inducing kinase, NIK. In NIH3T3 cells,
the Rac-NIK-IB kinase  pathway appears to be the primary
pathway for regulating NF-B function (12). In other cell types,
Rac1 can stimulate NF-B in a mitogen-activated protein ki-
nase/extracellular signal-regulated kinase kinase kinase 1-de-
pendent manner or by increasing the level of intracellular
reactive oxygen species (37–41). Reactive oxygen species can
stimulate IB kinase  via Src activation and subsequent stim-
ulation of protein kinase D activity via protein kinase C and
the Abl tyrosine kinase (42, 43). Activated PAK1 can stimulate
NF-B function, but it alone does not stimulate the activity of
IB kinase  or  (12, 44, 45). However, activated Rac1 with a
mutation of tyrosine at residue 40 was able to stimulate NF-B
in NIH3T3 cells (23). In NIH3T3 cells, we observed no stimu-
lation of NF-B by activated PAK1, whereas Rac1Q61L-40C
efficiently stimulated NF-B function. Thus, disruption of the
Rac1 to NF-B signal by Nischarin does not require PAK, but
may involve the pathways described above.
Rac1 plays a central role in mediating adhesion-dependent
signaling to cyclin D1 (25). In NIH3T3 cells, activated Rac1
stimulates cyclin D1 transcription via activation of NF-B
through cooperative interactions at a NF-B and an ATF-2
binding site in the cyclin D1 promoter. An activated Rac1 with
a mutated tyrosine 40 residue can also elicit this NF-B-de-
pendent activation of the cyclin D1 promoter (23). Similarly, we
observed that the Rac1Q61L-40C mutant retained the ability
to stimulate the cyclin D1 promoter. Furthermore, an activated
PAK1 was unable to stimulate the cyclin D1 promoter. Nischa-
rin repressed cyclin D1 promoter stimulation by Rac1Q61L-
40C, indicating that this repression is also independent of PAK.
Because Nischarin represses the ability of Rac to activate
NF-B function, the repression of cyclin D1 likely results from
reduced NF-B activation.
The inhibition of Rac1 function maps to the N terminus of
Nischarin. However, both Rac1Q61L and Rac1Q61L-40C form
complexes with both the N and C terminus of Nischarin. The
difference between these interactions with Rac1 may be their
differential cellular localization. Nischarin and the N terminus
exhibited similar patterns of co-localization with Rac1. Both
were found with Rac1 in the cytoplasm and vesicles. They
exhibited no co-localization with Rac1 in the nucleus. This
localization was not dependent on PAK because both
Rac1Q61L and RacQ61L-40C displayed a similar co-localiza-
tion. The C terminus exhibited a diffuse cytoplasmic and nu-
clear localization when present with both forms of activated
Rac1. There was not any strong vesicular co-localization with
the C terminus.
The cellular localization of Rac is critical for its function. The
translocation of active Rac1 to the plasma membrane facili-
tates the transduction of Rac1 signals to its effectors. Rho-GDI
bound to Rac1 in the cytoplasm inhibits its signaling. Activated
integrins direct translocation of Rac1 to cholesterol-rich, lipid
raft signaling complexes at the plasma membrane where Rac1
can signal. Internalization of these Rac1 containing lipid raft
signaling complexes dampen the Rac1 signal (26, 27). Disrup-
tion of macropinocytotic internalization of Rac1 with a domi-
nant negative dynamin-2 leads to aberrant localization of ac-
tive Rac1 and inhibition of lamellipodia formation (29).
Additionally, movement of Rac1 to the endocytic compartment
in an Arf6-dependent manner can repress the induction of
membrane ruffles of Rac1 (30). Interestingly, recent investiga-
tions indicate that active Rac1 stimulates the translocation of
the IB NF-B complex to the membrane. This membrane
localization of IB/NF-B facilitates activation of NF-B
through IB degradation (46).
The human Nischarin homolog, IRAS, has been recently
demonstrated to co-localize to early/sorting and recycling en-
dosomes and was postulated to be a sorting nexin. This local-
ization was dependent on a Phox domain and a coiled-coil
domain in the N terminus of IRAS. Elevated levels of IRAS
shifted 5 integrin from the membrane to the endosomal com-
partment (47). Nischarin lacks the Phox domain, but retains a
coiled-coil domain at aa 380–405 within the N terminus (48,
49). In NIH3T3 cells, this coiled-coil domain of Nischarin, and
the N terminus, may be sufficient for the formation of vesicles.
The co-localization of active Rac1 to these vesicles did not
require Rac1 interaction with PAK because the Rac1Q61L-40C
was also found to co-localize here. The vesicular co-localization
may contribute to the suppression of the Rac1 signal in the
presence of Nischarin or its N terminus by altering Rac1 cel-
lular localization as described above. The absence of vesicular
co-localization of the C terminus and Rac1 and the lack of an
effect of the C terminus on Rac1 signaling further suggests that
co-localization in these vesicular structures are important for
the negative regulation of Rac1 signaling by Nischarin.
Nischarin represses Rac1 signal transduction pathways by
PAK-dependent and -independent mechanisms. The ability to
repress the PAK arm of the Rac1 signal transduction cascade
results from the direct association of Nischarin with PAK. The
repression of the PAK-independent signals may result from
Nischarin altering the cellular localization of activated Rac1.
Additionally, suppression by Nischarin of other Rac1 effector
pathways may be mediated by the disruption of Rac1 interac-
tions with other effector molecules or the interaction of Nischa-
rin with and modulation of the function of other Rac1 effectors.
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